Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Advanced prostate cancer: the future.

Andrew J Armstrong¹, Michael A Carducci

¹Prostate Cancer Research Program, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.

The Canadian Journal of Urology

|July 16, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026

Same author

Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Cancer·2026

Same author

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

JCO precision oncology·2026

Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026

Same author

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Future oncology (London, England)·2026

Same author

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Prostate cancer and prostatic diseases·2026

Docetaxel offers survival benefits for metastatic hormone-refractory prostate cancer (HRPC). Further research into novel agents like cytotoxics and immunotherapy is crucial for improving patient outcomes in advanced prostate cancer.

Area of Science:

Oncology
Urology
Pharmacology

Background:

Metastatic hormone-refractory prostate cancer (HRPC) presents a significant challenge in advanced cancer care.
Docetaxel has shown survival benefits, but improvements in outcomes are still needed.
Current treatment paradigms require novel therapeutic strategies.

Purpose of the Study:

To review the current landscape of treatment options for advanced prostate cancer.
To highlight the role of docetaxel in HRPC management.
To discuss emerging novel agents and therapeutic approaches for advanced prostate cancer.

Main Methods:

Review of existing clinical data and ongoing research in advanced prostate cancer.
Analysis of docetaxel efficacy in HRPC.

Related Experiment Videos

Exploration of novel therapeutic categories including cytotoxics, immunotherapy, and targeted antibodies.

Main Results:

Docetaxel demonstrates a survival benefit in metastatic HRPC.
Docetaxel-based therapy improves symptomatic and quality-of-life endpoints.
Novel agents targeting specific mechanisms of prostate cancer are under development.

Conclusions:

Docetaxel is an important treatment for advanced prostate cancer.
There is a critical need for enhanced therapeutic strategies to improve outcomes.
Emerging novel agents offer promising avenues for future HRPC treatment.